These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 3322837

  • 1. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD.
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [Abstract] [Full Text] [Related]

  • 2. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP, Marion MH, Marsden CD.
    Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
    [Abstract] [Full Text] [Related]

  • 3. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH, Lees AJ, Stern GM.
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [Abstract] [Full Text] [Related]

  • 4. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN, Meerwaldt JD, Heersema T, van Manen J, Speelman JD.
    Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
    [Abstract] [Full Text] [Related]

  • 5. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD.
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract] [Full Text] [Related]

  • 6. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C, Romero S, de Medina O, Aljanati R, Scarmelli A, Caamano JL, Gonzales Panizza V.
    Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
    [Abstract] [Full Text] [Related]

  • 7. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
    Crevoisier C, Hoevels B, Zürcher G, Da Prada M.
    Eur Neurol; 1987; 27 Suppl 1():36-46. PubMed ID: 3428308
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 9. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO.
    Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
    [Abstract] [Full Text] [Related]

  • 10. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
    Nordera GP, Lorizio A, Lion P, Durisotti C, D'Andrea G, Ferro-Milone F.
    Eur Neurol; 1987; 27 Suppl 1():76-80. PubMed ID: 3322839
    [Abstract] [Full Text] [Related]

  • 11. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
    Fischer PA, Baas H.
    Eur Neurol; 1987; 27 Suppl 1():81-7. PubMed ID: 3322840
    [Abstract] [Full Text] [Related]

  • 12. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H.
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [Abstract] [Full Text] [Related]

  • 13. Open clinical study of Madopar HBS.
    Ludin HP.
    Eur Neurol; 1987 Feb; 27 Suppl 1():73-5. PubMed ID: 3322838
    [Abstract] [Full Text] [Related]

  • 14. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
    Rinne UK.
    Eur Neurol; 1987 Feb; 27 Suppl 1():120-5. PubMed ID: 3428305
    [Abstract] [Full Text] [Related]

  • 15. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G, Tesei S, Ferrante C, Cossutta E, Zecchinelli A, Scarlato G.
    Mov Disord; 1988 Feb; 3(1):37-45. PubMed ID: 3050471
    [Abstract] [Full Text] [Related]

  • 16. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
    Graham JS, Henderson JM, Morris JG, Yiannikas C.
    Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070
    [Abstract] [Full Text] [Related]

  • 17. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C, Monreal A, Metzger B, Nilsen T.
    Eur Neurol; 2003 Feb; 49(1):39-44. PubMed ID: 12464717
    [Abstract] [Full Text] [Related]

  • 18. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ.
    Eur Neurol; 1987 Feb; 27 Suppl 1():126-34. PubMed ID: 3428306
    [Abstract] [Full Text] [Related]

  • 19. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Eur Neurol; 1987 Feb; 27 Suppl 1():114-9. PubMed ID: 3322835
    [Abstract] [Full Text] [Related]

  • 20. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS, Covicković-Sternić N.
    Neurologija; 1990 Feb; 39(2):99-105. PubMed ID: 2267052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.